More cystic fibrosis (CF) patients in Saskatchewan now have access to Trikafta, a groundbreaking medication that improves lung function and quality of life. As of November 15, the province has ...

Astrazeneca plc has developed a potent oral fibroblast activation protein (FAP) inhibitor, AZD-2389, that avoids the cleavage of FGF21 and α2-AP. AZD-2389 was tested in cynomolgus monkeys with ...

The firm's chief scientific officer called the achievement "a major milestone for Spirovant and for the cystic fibrosis ...

Boston Pharma’s once-monthly injection efimosfermin alfa offers a convenient dosing option for MASH patients while also ...